Use of GLP-1 receptor agonists was associated with a twofold higher risk for neovascular age-related macular degeneration development in a population-based study published in JAMA Ophthalmology.
“It has been postulated that the rapid reduction in blood glucose levels triggered by GLP-1 RAs leads to a hypoxic state of the retina that promotes further abnormal angiogenesis,” Reut Shor, MD, of the department of ophthalmology and vision sciences at the University of Toronto, and colleagues wrote. “Given that the underlying pathogenesis of [neovascular AMD] involves abnormal and